Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Immuno-Oncology Europe 2019

Stephen Beers's Biography

Stephen Beers, Professor of Immunology and Immunotherapy, University of Southampton

Stephen Beers is Professor of Immunology and Immunotherapy at the Centre for Cancer Immunology, University of Southampton. He leads a research group studying antibody drugs and their mechanisms of action. The group’s research is currently focussed on two main areas: 1) the mechanisms of action of immunomodulatory mAb, and 2) how the tumour microenvironment affects antibody effector function and how this might be manipulated to enhance patient outcomes. Their work utilises a portfolio of complimentary models incorporating in vitro 3D modelling, appropriate in vivo model systems and primary clinical material.

Stephen Beers Image

Optimizing Anti-Cancer Therapy with Immune Stimulatory Antibodies: Big Doors Swing on Little Hinges

Monday, 28 October 2019 at 14:00

Add to Calendar ▼2019-10-28 14:00:002019-10-28 15:00:00Europe/LondonOptimizing Anti-Cancer Therapy with Immune Stimulatory Antibodies: Big Doors Swing on Little HingesImmuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The

Clinical successes with immunomodulatory monoclonal antibodies (mAb) have confirmed that the adaptive immune system can produce long-term cures for cancer patients. These remarkable findings with immunomodulatory mAb have, to date, been restricted to checkpoint blockers with their co-stimulatory counterparts failing to translate. Here, data will be presented that illustrates the mechanistic complexity of co-stimulatory mAb targeting 4-1BB (CD137). We will show that these mAb are able to perform multiple functions with opposing Fc?R requirements. Further, we will demonstrate that inappropriate Fc selection can lead to blunted responses that limit efficacy. Finally, once the mechanistic requirements for therapeutic efficacy are established we show that these can be used to design optimal combination therapies and to engineer single agent combination mAb. These data provide a framework for engineering co-stimulatory mAb for clinical translation.

Add to Calendar ▼2019-10-28 00:00:002019-10-29 00:00:00Europe/LondonImmuno-Oncology Europe 2019Immuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The